More recent studies investigating the semisynthetic FXR agonist, Obeticholic acid (OCA), conducted exclusively in adults with NASH, showed reduction in insulin resistance, steatohepatitis, levels of ALT and fibrosis in these patients. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.